Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ruxolitinib when given together
with venetoclax in treating patients with acute myeloid leukemia that has come back
(relapsed) or has not responded to treatment (refractory). Ruxolitinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the
growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. This
study is being done to see if the combination of ruxolitinib and venetoclax works better in
treating patients with acute myeloid leukemia compared to standard of care chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
Brian Druker OHSU Knight Cancer Institute
Collaborators:
AbbVie Incyte Corporation National Cancer Institute (NCI) Oregon Health and Science University